Small Molecule CMO/CDMO Market Report 2026

The small molecule cmo/cdmo market size has grown strongly in recent years. It will grow from $54.42 billion in 2025 to $58.55 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to growth in generic drug manufacturing, rising prevalence of chronic diseases, expansion of pharmaceutical R&D, outsourcing of drug production, regulatory push for quality and safety.

The small molecule cmo/cdmo market size is expected to see strong growth in the next few years. It will grow to $78.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising investments in biologics and small-molecule hybrid therapies, expansion in emerging markets, technological advancements in synthesis and formulation, growing need for faster regulatory approvals. Major trends in the forecast period include expansion of contract development and manufacturing services, increasing adoption of continuous manufacturing processes, growth in custom synthesis of small-molecule apis, rising focus on regulatory compliance and quality assurance, strategic partnerships between pharma companies and cmos.

The increasing demand for pharmaceuticals is expected to drive the growth of the small-molecule CMO/CDMO market in the coming years. The pharmaceutical industry is a field that encompasses the discovery, development, and production of drugs and medicines by both government and private organizations. Small-molecule CMO/CDMO services are utilized in the pharmaceutical industry to outsource various activities, including the development, manufacturing, and packaging of small-molecule drugs, enabling pharmaceutical companies to reduce costs, save time, and optimize processes. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, as of January 2022, the U.S. had 33 FDA-approved biosimilar products, with 21 available on the market, and by 2023, the number of FDA-approved biosimilars had increased to 40, with 25 commercially available. Thus, the growing demand for pharmaceuticals is contributing to the expansion of the small-molecule CMO/CDMO market.

Major companies operating in the small-molecule CMO/CDMO market are emphasizing innovative technologies, such as the advanced small-molecule platform in Shanghai, to enhance CDMO services. The advanced small-molecule platform represents the leading edge of technological innovations for developing and producing small-molecule drugs, aiming to create safer, more effective, and more efficiently manufactured pharmaceutical compounds. For example, in June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched an advanced small-molecule platform in Shanghai, enhancing CDMO services. An advanced small-molecule platform represents a comprehensive approach, integrating cutting-edge technologies and methodologies to support the entire lifecycle of small-molecule pharmaceuticals, offering one-stop-shop solutions, end-to-end capabilities, flexibility and availability, and digital transformation.

In February 2024, Novo Holdings A/S, a Denmark-based investment firm, acquired Catalent, Inc. for $16.5 billion. Through this acquisition, Novo Holdings aims to enhance its global CDMO capabilities by utilizing Catalent’s extensive manufacturing network and expertise in the development, production, and supply of small-molecule and biologic therapies. Catalent, Inc. is a US-based company that provides small-molecule contract development and manufacturing (CDMO) services.

Major companies operating in the small molecule cmo/cdmo market are Patheon NV (Thermo Fisher Scientific), Johnson Matthey plc, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Dishman Carbogen Amcis Ltd, ProChem Inc., Metrics Contract Services.

North America was the largest region in the small molecule CMO/CDMO market in 2025. The regions covered in the small molecule cmo/cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small molecule cmo/cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the small molecule CMO/CDMO market by increasing the cost of imported raw materials, APIs, and specialized manufacturing equipment, leading to higher production costs and supply chain delays. The commercial and preclinical small molecule drug segments, especially in regions such as North America and Asia-Pacific, are most affected due to reliance on cross-border sourcing. However, tariffs are encouraging local manufacturing initiatives and strategic supplier diversification, which may strengthen regional capabilities and reduce long-term dependency on imports.

The small molecule cmo/cdmo market research report is one of a series of new reports that provides small molecule cmo/cdmo market statistics, including small molecule cmo/cdmo industry global market size, regional shares, competitors with a small molecule cmo/cdmo market share, detailed small molecule cmo/cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule cmo/cdmo industry. This small molecule cmo/cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) is a company that provides services to other pharmaceutical companies on a contract basis for the execution of projects and subsequent regulatory submission. These organizations provide a variety of services, including contract development, manufacturing, and packaging of small-molecule drugs.

The main types of small-molecule CMO and CDMO are small-molecule drug products and small-molecule APIs. A small-molecule drug product refers to the final form of a medicinal product that contains an active pharmaceutical ingredient (API) made up of small molecules. It encompasses various stages, including clinical, commercial, and preclinical, is applied in oncology, neurology, infectious disease, cardiovascular disease, respiratory disorders, metabolic disorders, and others, and the end users are cardiovascular, oncology, diabetes, and immunological disorder patients.

The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as drug development services, process scale-up, quality control and testing, technology transfer, and clinical trial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market also includes sales of active pharmaceutical ingredients, drug intermediates, and drug formulation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.